Two innovative treatments for Ebola hemorrhagic fever are being developed, with a low viral load and nearly 90% survival
Ebola hemorrhagic fever is a viral infection that causes symptoms such as fever, muscle pain, vomiting, and diarrhea, and is considered dangerous worldwide because of its extremely high fatality rate. It was reported that such a new treatment for Ebola hemorrhagic fever was highly effective in the experiment and could be used for treatment in the Democratic Republic of the Congo where Ebola hemorrhagic fever is prevalent.
Ebola Is Now Curable. Here's How the New Treatments Work | WIRED
Regeneron's Ebola Drug Saves Lives in Heart of Congo Outbreak-Bloomberg
In July 2019, the World Health Organization (WHO) declared an internationally concerned public health emergency (PHEIC) for the epidemic of Ebola in Central Africa and the Democratic Republic of the Congo. In the Democratic Republic of the Congo, infection of Ebola has spread since August 2018, and at the time of writing the article, more than 2,800 people were infected and more than 1,800 people were thought to have died.
Declaration of emergency situation regarding epidemic in Congo with more than 1600 deaths of Ebola hemorrhagic fever, concern about the spread of international infection-GIGAZINE
Meanwhile, in the Democratic Republic of the Congo, doctors and researchers are conducting clinical trials of new drugs against Ebola hemorrhagic fever in cooperation with WHO and the National Institutes of Health . Clinical experiments have been conducted since November 2018 at four treatment centers in the eastern Democratic Republic of the Congo, where Ebola infection is serious, and various types of treatments have been administered to patients to collect data such as survival rates. It was.
The drugs used in the clinical experiment include two types of conventional Ebola hemorrhagic fever treatments, Zmapp and remdesivir , and REGN-EB3 developed by a pharmaceutical company called Regeneron Pharmaceuticals, which was prepared for comparison by the National Institute of Allergy and Infectious Diseases. Two new drugs, mAb114 , were developed.
According to experimental data administered to a total of 681 patients, the mortality rate was 49% for patients treated with Zmapp, a conventional treatment, and 53% for patients treated with remdesivir. This greatly improved the 75% mortality rate for patients who were not treated. However, the mortality rate of patients treated with REGN-EB3 was 29%, and 34% with mAb114, which revealed that the two new drugs were much more effective than Zmapp.
Furthermore, for patients with low levels of virus in the body and shortly after infection, the mortality rate of patients treated with REGN-EB3 has been reduced to only 6% and mAb114 to 11%. Originally a clinical experiment was planned for 725 patients, but it was confirmed that REGN-EB3 and mAb114 had already been sufficiently effective, and that future patients will be treated with two new drugs. doing.
Originally, Ebola was a highly mortal infection, but in recent years, the mortality rate has been further increased if the infected person is not treated, and many patients die without treatment in the community. It is said that. Anthony Fouch , director of the National Institute of Allergy and Infectious Diseases, who developed mAb114 , said, “We got a cure for a disease that we had never been able to treat. “You may be able to increase your willingness to survive and your motivation for treatment,” he commented.
Jean Jacques Muembe, director of the National Institute of Biomedical Research in the Democratic Republic of the Congo and director of clinical experiments, said, “This progress has had the effect of saving thousands of lives that were fatal in the past. I have already argued that Ebola is not a curable disease.
in Science, Posted by log1h_ik